Palvella Therapeutics PVLA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's operating cash flow?
- Palvella Therapeutics (PVLA) reported operating cash flow of -$10.86M in Q1 2026.
- How has Palvella Therapeutics's operating cash flow changed year-over-year?
- Palvella Therapeutics's operating cash flow decreased by 60.5% year-over-year, from -$6.77M to -$10.86M.
- What is the long-term trend for Palvella Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Palvella Therapeutics's operating cash flow has grown at a 48.3% compound annual growth rate (CAGR), from -$7.66M to -$25.01M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.